Gilead Sciences Partners with Tubulis to Develop Next-Generation Antibody-Drug Conjugate for Solid Tumors

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover...

December 04, 2024 | Wednesday | News
Orikine Bio Secures €800k Funding to Accelerate Development of ORK-1 for Autoimmune Diseases

Orikine Bio, a pioneering biopharmaceutical company focused on the discovery, research and development of precision-engineered bi-specific cytokine therapi...

December 04, 2024 | Wednesday | News
Merck’s Sacituzumab Tirumotecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthroug...

December 04, 2024 | Wednesday | News
Polyrizon Signs Manufacturing Agreement with Eurofins CDMO for PL-14 Allergy Blocker Clinical Trial

Polyrizon Ltd. (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, anno...

December 03, 2024 | Tuesday | News
Jasper Therapeutics Doses First Patient in Phase 1b/2a ETESIAN Study of Briquilimab for Allergic Asthma

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy t...

December 03, 2024 | Tuesday | News
Kelun-Biotech's Sacituzumab Tirumotecan (Sac-TMT) Gains Marketing Approval for Advanced TNBC in China

The competition among three TROP2 antibody-drug conjugates is entering a new stage as Kelun-Biotech’s Merck & Co.-partnered sacituzumab...

December 02, 2024 | Monday | News
Renalys Pharma's Sparsentan Receives Orphan Drug Designation for Primary IgA Nephropathy in Japan

Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. ("Trav...

December 02, 2024 | Monday | News
Aulos Bioscience Doses First Patient in Phase 2 Trial for Second-Line PD-L1+ NSCLC Treatment

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, tod...

November 29, 2024 | Friday | News
Ascentage Pharma’s Olverembatinib Gains Expanded Inclusion in China’s 2024 National Reimbursement Drug List

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet med...

November 29, 2024 | Friday | News
Eisai and Biogen Launch LEQEMBI® for Early Alzheimer's Treatment in South Korea

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

November 28, 2024 | Thursday | News
Acadia Pharmaceuticals Licenses SAN711 from Saniona for Essential Tremor, Expanding Neurology Pipeline

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the develo...

November 27, 2024 | Wednesday | News
Amgen Announces Promising Phase 2 Results for MariTide, Showing Significant Weight Loss and Cardiometabolic Improvements

Amgen (NASDAQ:AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly...

November 27, 2024 | Wednesday | News
Alnylam's Vutrisiran sNDA Accepted by FDA for Priority Review in ATTR-CM with March 2025 Decision Expected

 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration&n...

November 26, 2024 | Tuesday | News
Zevra Therapeutics Launches MIPLYFFA™, the First FDA-Approved Treatment for Niemann-Pick Disease Type C

MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense AmplifyAssist&...

November 22, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close